Editorial: Are thiopurines and Anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease

American Journal of Gastroenterology

Volumn 108, Issue 3, 2013, Pages 441-443

  Sheibani, Sarah ^a   Mahadevan, Uma ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; MERCAPTOPURINE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

CHILD DEVELOPMENT; DISEASE ACTIVITY; DRUG SAFETY; ENTERITIS; FOLLOW UP; HUMAN; MONOTHERAPY; OUTCOME ASSESSMENT; PREGNANCY; PREGNANCY OUTCOME; PRIORITY JOURNAL; REVIEW;

6-MERCAPTOPURINE; ANTIBODIES, MONOCLONAL; AZATHIOPRINE; FEMALE; HUMANS; INFLAMMATORY BOWEL DISEASES; PREGNANCY; PREGNANCY COMPLICATIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875163789     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2012.436     Document Type: Review

References (21)

1. Casanova MJ, Chaparro M, Domenech E. Safety of thiopurines and anti- TNF drugs during pregnancy in patients with inflammatory bowel disease. Am J Gastroenterol 2013;108:433-40 (this-issue).
2. Loftus E, Sandborn W. Epidemiology of Inflammatory Bowel Disease. Gastroenterol Clin N Am 2002; 31: 1-20.
3. Nielsen O, Andreasson B, Bondesen S. Pregnancy in ulcerative colitis. Scan J Gastroenterol 1983; 18: 735-42.
4. Mogadam M, Korelitz BI, Ahmed SW. The course of inflammatory bowel disease during pregnancy and postpartum. Am J Gastroenterol 1981; 75: 265-9.
5. Mahadevan U, Sandborn W, Li DK. Pregnancy outcomes in women with inflammatory bowel disease: a large community-based study from Northern California. Gastroenterology 2007; 133: 1106-12.
6. Bush MC, Patel S, Lapinksi RH. Perinatal outcomes in inflammatory bowel disease. J Matern Fetal Neonatal Med 2004; 15: 237-41
7. Reddy D, Murphy S, Kane S. Relapse of inflammatory bowel disease during pregnancy: in-hospital management and birth outcomes. Am J Gastroenterol 2008; 103: 1203-9.
8. Norgard B, Hundborg HH, Jacobsen BA. Disease activity in pregnant women with Crohn's disease and birth outcomes: a regional Danish Cohort study. Am J Gastroenterol 2007; 102: 1947-54.
9. Mahadevan U, Cucchiara S, Hyams J. The London position statement of the world congress of gastroenterology on biological therapy for IBD with the European Crohn's and Colitis organization: pregnancy and pediatrics. Am J Gastroenterol 2011; 105: 214-23.
10. Akbari B, Shah S, Velayos F. Systematic review and meta-analysis on the effects of thiopurines on birth outcomes from female and male patients with inflammatory bowel disease. Inflamm Bowel Disease; advance online publication, 20 March 2012 (E-pub ahead of print).
11. Norgard B, Pedersen L, Christensen L. Therapeutic drug use in women with Crohn's disease and birth outcomes: a Danish Nationwide Cohort Study. Am J Gastroenterol 2007; 102: 1406-13.
12. Shim L, Eslick GD, Simring AA. The effects of Azathioprine on birth outcomes in women with inflammatory bowel disease (IBD). J Crohns Colitis 2011; 5: 234-8.
13. Mahadevan U, Kane S, Sanborn WJ. Intentional infl iximab use during pregnancy for induction or maintenance of remission in Crohn's disease. Aliment Pharmacol Ther 2005; 21: 733-8.
14. Katz JA, Antoni C, Keenan GF. Outcomes of pregnancy in women receiving infl iximab for the treatment of Crohn's disease and rheumatoid arthritis. Am J Gastroenterol 2004; 99: 2385-92.
15. Schnitzler F, Fidder H, Ferrante M. Outcome in pregnancy in women with inflammatory bowel disease with antitumor necrosis factor therapy. Inflamm Bowel Dis 2011; 17: 1846-54.
16. Carter D, Ladhani A, Ricca L. A safety assessment of tumor necrosis factor antagonists during pregnancy: a review of the food and drug administration database. J Rheumatol 2009; 36: 635-41.
17. Mahadevan U, Martin C, Sandler R. PIANO: a 1000 patient prospective registry of pregnancy outcomes in women with IBD exposed to immunomodulators and biologic therapy 2012, DDW.
18. Nasef NA, Ferguson LR. Inflammatory bowel disease and pregnancy: overlapping pathways. Transl Res 2012; 160: 65-83.
19. Palmeira P, Quinello C, Silveira-Lessa AL. IgG placental transfer in healthy and pathological pregnancies. Clin Dev Immunol 2012; 2012-985646.
20. Mahadevan U, Wolf DC, Dubinsky M et al. Placental transfer of antitumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol; advance online publication, 27 November 2012 (E-pub ahead of-print).
21. Zelinkova Z, de Haar C, De Ridder L. High intra-uterine exposure to infl iximab following maternal anti-TNF treatment during pregnancy. Aliment Pharmacol Ther 2011; 33: 1053-8.